Loading
companiesCompany
Shanghai Yingli Pharmaceutical
Shanghai Yingli Pharmaceutical developed linperlisib, the PI3K-delta inhibitor approved in China in 2022 for relapsed follicular lymphoma.
Also called: Yingli Pharma
Overview
Shanghai Yingli Pharmaceutical is a small-molecule company in Shanghai's Zhangjiang science park. Its PI3K-delta inhibitor linperlisib (YY-20394) received conditional NMPA approval in November 2022 for relapsed or refractory follicular lymphoma after two or more lines, and is in trials in peripheral T-cell lymphoma and solid tumours.
Headquarters
Shanghai, China, CN
Scorecard
All companies#265of 1244 companies, score 18
- approved products +6
- modalities +2
- regions +1
- registry trials +9
1 approved, 0 in phase 3, 0 earlier, 0 targets, 21 registry studies. Formula on the scorecards page.
Type
Stage
Growth stage
Website
ApprovedOral PI3K-delta inhibitor
Linperlisib is Shanghai Yingli's PI3K-delta inhibitor, approved in China in 2022 for relapsed or refractory follicular lymphoma after two or more lines.
Similar pages
- TrialALTER 0303
Shares Small-molecule kinase inhibitors and the tag china.
- TrialZGDH3 (donafenib vs sorafenib)
Shares Small-molecule kinase inhibitors and the tag china.
- TrialAENEAS
Shares Small-molecule kinase inhibitors and the tag china.
- TreatmentIcotinib
Shares Small-molecule kinase inhibitors and the tag china.
- TreatmentRelmacabtagene autoleucel
Shares Follicular lymphoma and the tag china.
- TreatmentOrelabrutinib
Shares Small-molecule kinase inhibitors and the tag china.
- TreatmentDonafenib
Shares Small-molecule kinase inhibitors and the tag china.
- TreatmentDalpiciclib
Shares Small-molecule kinase inhibitors and the tag china.
cancers
technologies
drugs
ApprovedOral PI3K-delta inhibitor